Novel Immune Response Evasion Strategy to Redose Adeno-associated Viral Vectors and Prolong Survival in Surfactant Protein-B Deficient Mice.

Surfactant protein-B (SP-B) deficiency is a lethal neonatal respiratory disease with few therapeutic options. Gene therapy using adeno-associated viruses (AAV) to deliver human cDNA (AAV-hSPB) can improve survival in a mouse model of SP-B deficiency. However, the effect of this gene therapy wanes.

Neonatal and Home-Based PT Improves Neurodevelopmental Outcomes of Preterm Infants-A Randomized Clinical Trial.

Purpose: Investigate the effect of structured neonatal physical therapy program (SNP) on neurodevelopmental outcomes of moderate and late preterm (MLP) infants.

Methods: Sixty MLP infants were randomly allocated to usual care (UC) or SNP. A previous publication reported the effect of neonatal component of SNP at hospital discharge.

Nation-wide cross-sectional study of participation and predictors of enjoyment among Australian adult walking sport participants.

This study examined participation and predictors of walking sports enjoyment among Australian adult walking sport participants. An online cross-sectional survey assessed walking sport participation, enjoyment, and barriers and motives to participation. Physical activity behavior and motivations were also assessed.

Differentiating BOLD and non-BOLD signals in fMRI time series using cross-cortical depth delay patterns.

Over the past two decades, rapid advancements in magnetic resonance technology have significantly enhanced the imaging resolution of functional Magnetic Resonance Imaging (fMRI), far surpassing its initial capabilities. Beyond mapping brain functional architecture at unprecedented scales, high-spatial-resolution acquisitions have also inspired and enabled several novel analytical strategies that can potentially improve the sensitivity and neuronal specificity of fMRI. With small voxels, one can sample from different levels of the vascular hierarchy within the cerebral cortex and resolve the temporal progression of hemodynamic changes from parenchymal to pial vessels.

Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.

Background: This study is a phase II clinical trial to evaluate the efficacy, safety, and tolerability of the blood-brain barrier (BBB) permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma (HGG) (NCT01967810).

Methods: Seventy-three patients were enrolled in 3 separate arms-recurrent glioblastoma (GBM) (Arm 1), bevacizumab refractory GBM (Arm 2), and grade 3 anaplastic gliomas (AGs) (Arm 3). The study was started in October 2013, and the data were locked on September 29, 2017.